Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELTX | US
0.89
8.21%
Healthcare
Biotechnology
30/06/2024
14/04/2026
11.73
10.91
11.79
10.82
Elicio Therapeutics Inc. a clinical-stage biotechnology company engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002 an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004 an AMP-modified CpG adjuvant a component of ELI-002 to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005 a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P) a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines adjuvants and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS INC. and changed its name to Elicio Therapeutics Inc. on September 18 2019. The company was incorporated in 2011 and is headquartered in Boston Massachusetts.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
66.6%1 month
66.3%3 months
84.9%6 months
72.6%5.18
-
10.11
-3.89
0.41
-2.61
-
-
-41.00M
122.80M
122.80M
-
-
-
-
-353.02
2.36
0.45
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.94
Range1M
2.88
Range3M
7.56
Rel. volume
1.20
Price X volume
1.54M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| AVTX | AVTX | Biotechnology | 13.9 | 134.83M | 4.20% | n/a | -80.47% |
| NRXPW | NRXPW | Biotechnology | 0.01 | 134.58M | -16.67% | n/a | -46.73% |
| ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 3.2 | 132.43M | -0.62% | 6.60 | -7.70% |
| Tiziana Life Sciences PLC | TLSA | Biotechnology | 1.29 | 130.95M | 12.17% | n/a | 0.00% |
| Quanterix Corporation | QTRX | Biotechnology | 3.39 | 130.10M | 0.00% | n/a | 11.75% |
| Achieve Life Sciences Inc | ACHV | Biotechnology | 3.61 | 123.97M | 0.84% | n/a | 41.73% |
| Corbus Pharmaceuticals Holdings Inc | CRBP | Biotechnology | 10.02 | 120.68M | -1.57% | n/a | 11.79% |
| QSI | QSI | Biotechnology | 0.8408 | 119.70M | 6.61% | n/a | 0.71% |
| Seer Inc. | SEER | Biotechnology | 1.94 | 119.17M | 1.04% | n/a | 7.43% |
| Mawson Infrastructure Group Inc. Common Stock | MIGI | Biotechnology | 6.12 | 113.55M | 24.90% | n/a | 571.64% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.41 | 98.82M | -0.81% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.06 | 98.71M | 3.59% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.98 | 75.01M | 2.45% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.6 | 65.02M | 1.12% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14.75 | 22.46M | 41.83% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.91 | 13.30M | 3.42% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.623 | 12.04M | 3.83% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.32 | 3.37M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2149 | 2.05M | -5.58% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.87 | 1.03M | -9.66% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.61 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | 5.18 | 41.03 | Cheaper |
| Price to Book | 10.11 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 84.89 | - | Par |
| Debt to Equity | -3.89 | -1.23 | Cheaper |
| Debt to Assets | 0.41 | 0.25 | Expensive |
| Market Cap | 122.80M | - | Emerging |